Clinical trials


Durvalumab (MEDI4736) After chemoRadioTherapy for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients More information	Nivolumab and Ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma – a phase II randomised clinical and translational trial More information
	NorPACT-2
Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer (COM-IT-2) – a phase II randomised clinical and translational trial More information	Norwegian Pancreatic Cancer Trial (NorPACT)-2: Liquid biopsies and blood-based biomarkers (https://www.ous-research.no/ pancreaticcancer)

Scroll to top

Recent publications

Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A (2023)
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
Eur J Cancer, 194, 113278
DOI 10.1016/j.ejca.2023.113278, PubMed 37820553

Børø S, Thoresen S, Boge Brant S, Helland Å (2023)
Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer
Acta Oncol, 62 (12), 1642-1648
DOI 10.1080/0284186X.2023.2264484, PubMed 37801361

Yi D, Grøvik E, Tong E, Iv M, Emblem KE, Nilsen LB, Saxhaug C, Latysheva A, Jacobsen KD, Helland Å, Zaharchuk G, Rubin D (2023)
Erratum: "MRI pulse sequence integration for deep-learning-based brain metastases segmentation"
Med Phys, 50 (8), 5294
DOI 10.1002/mp.16594, PubMed 37573581

More publications

NorPACT-2